RESUMEN
THE AIM OF STUDY: To assess some risk factors and their involvement in female breast tumours etiology. MATERIAL AND METHODS: The study was performed on a sample of 67 patients registered with breast tumours, at family phisicians' offices from Iasi, Romania. RESULTS: Some risk factors were defined such as: nuliparity (20.8%) and first pregnancy after age 30 (34.3%); fibrous mastopathy in personal history (73.1% of cases with breast cancer) and breast cancer in siblings of first (8.9%) and second grade (11.9%). Relative to lifestyle, sedentary life was remarked in 59.2% of patients; modification of circadian rhythm in 28.3%, and excesive caffeine consumption in 80.9% of cases. CONCLUSIONS: Further prevention and educational programs on breast tumoural risk factors are needed in Romania, even at female teenage, performed by family physician.
Asunto(s)
Neoplasias de la Mama/etiología , Neoplasias de la Mama/prevención & control , Adulto , Anciano , Ritmo Circadiano , Café/efectos adversos , Femenino , Enfermedad Fibroquística de la Mama/complicaciones , Conductas Relacionadas con la Salud , Humanos , Edad Materna , Persona de Mediana Edad , Paridad , Educación del Paciente como Asunto , Embarazo , Complicaciones Neoplásicas del Embarazo/diagnóstico , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Rumanía , Muestreo , Conducta SedentariaRESUMEN
UNLABELLED: The aim of study was to assess some investigations in female patients with benign and malignant breast diseases. MATERIAL AND METHODS: The study was performed on a sample of 104 patients registered with breast tumors, at family physicians' offices from Iasi, Romania. RESULTS: Impaired glucose tolerance was associated with 34.2% of patient with breast tumors, and hypercholesterolemia with 25.9% of them. Anatomo-pathological assessments included aspiration puncture and biopsy, extemporaneous biopsy, and paraffin-embedded exam. Invasive carcinoma was the most frequent histo-pathological type (42.1%). CONCLUSIONS; Further investigations on tumor markers are needed in all patients with in situ neoplasia and breast carcinomas.